Amy A Mrazek1, Laura J Porro1, Vandanajay Bhatia2, Miriam Falzon3, Heidi Spratt4, Jia Zhou2, Celia Chao5, Mark R Hellmich6. 1. Department of Surgery, University of Texas Medical Branch, Galveston, Texas. 2. Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas. 3. Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas; Sealy Center for Cancer Cell Biology, University of Texas Medical Branch, Galveston, Texas. 4. Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, Texas. 5. Department of Surgery, University of Texas Medical Branch, Galveston, Texas; Sealy Center for Cancer Cell Biology, University of Texas Medical Branch, Galveston, Texas. Electronic address: cechao@utmb.edu. 6. Department of Surgery, University of Texas Medical Branch, Galveston, Texas; Sealy Center for Cancer Cell Biology, University of Texas Medical Branch, Galveston, Texas.
Abstract
BACKGROUND: Chronic pancreatitis (CP) is characterized by recurrent pancreatic injury, resulting in inflammation, necrosis, and fibrosis. There are currently no drugs limiting pancreatic fibrosis associated with CP, and there is a definite need to fill this void in patient care. MATERIALS AND METHODS: Pancreatitis was induced in C57/BL6 mice using supraphysiologic doses of cerulein, and apigenin treatment (once daily, 50 μg per mouse by oral gavage) was initiated 1 wk into the recurrent acute pancreatitis (RAP) protocol. Pancreata were harvested after 4 wk of RAP. Immunostaining with fibronectin antibody was used to quantify the extent of pancreatic fibrosis. To assess how apigenin may decrease organ fibrosis, we evaluated the effect of apigenin on the proliferation and apoptosis of human pancreatic stellate cells (PSCs) in vitro. Finally, we assessed apigenin's effect on the gene expression in PSCs stimulated with parathyroid hormone-related protein, a profibrotic and proinflammatory mediator of pancreatitis, using reverse transcription-polymerase chain reaction. RESULTS: After 4 wk of RAP, apigenin significantly reduced the fibrotic response to injury while preserving acinar units. Apigenin inhibited viability and induced apoptosis of PSCs in a time- and dose-dependent manner. Finally, apigenin reduced parathyroid hormone-related protein-stimulated increases in the PSC messenger RNA expression levels of extracellular matrix proteins collagen 1A1 and fibronectin, proliferating cell nuclear antigen, transforming growth factor-beta, and interleukin-6. CONCLUSIONS: These in vivo and in vitro studies provide novel insights regarding apigenin's mechanism(s) of action in reducing the severity of RAP. Additional preclinical testing of apigenin analogs is warranted to develop a therapeutic agent for patients at risk for CP.
BACKGROUND:Chronic pancreatitis (CP) is characterized by recurrent pancreatic injury, resulting in inflammation, necrosis, and fibrosis. There are currently no drugs limiting pancreatic fibrosis associated with CP, and there is a definite need to fill this void in patient care. MATERIALS AND METHODS:Pancreatitis was induced in C57/BL6 mice using supraphysiologic doses of cerulein, and apigenin treatment (once daily, 50 μg per mouse by oral gavage) was initiated 1 wk into the recurrent acute pancreatitis (RAP) protocol. Pancreata were harvested after 4 wk of RAP. Immunostaining with fibronectin antibody was used to quantify the extent of pancreatic fibrosis. To assess how apigenin may decrease organ fibrosis, we evaluated the effect of apigenin on the proliferation and apoptosis of humanpancreatic stellate cells (PSCs) in vitro. Finally, we assessed apigenin's effect on the gene expression in PSCs stimulated with parathyroid hormone-related protein, a profibrotic and proinflammatory mediator of pancreatitis, using reverse transcription-polymerase chain reaction. RESULTS: After 4 wk of RAP, apigenin significantly reduced the fibrotic response to injury while preserving acinar units. Apigenin inhibited viability and induced apoptosis of PSCs in a time- and dose-dependent manner. Finally, apigenin reduced parathyroid hormone-related protein-stimulated increases in the PSC messenger RNA expression levels of extracellular matrix proteins collagen 1A1 and fibronectin, proliferating cell nuclear antigen, transforming growth factor-beta, and interleukin-6. CONCLUSIONS: These in vivo and in vitro studies provide novel insights regarding apigenin's mechanism(s) of action in reducing the severity of RAP. Additional preclinical testing of apigenin analogs is warranted to develop a therapeutic agent for patients at risk for CP.
Authors: M V Apte; P S Haber; T L Applegate; I D Norton; G W McCaughan; M A Korsten; R C Pirola; J S Wilson Journal: Gut Date: 1998-07 Impact factor: 23.059
Authors: M G Bachem; E Schneider; H Gross; H Weidenbach; R M Schmid; A Menke; M Siech; H Beger; A Grünert; G Adler Journal: Gastroenterology Date: 1998-08 Impact factor: 22.682
Authors: Fahadul Islam; Jannatul Fardous Khadija; Md Rezaul Islam; Sheikh Shohag; Saikat Mitra; Saad Alghamdi; Ahmad O Babalghith; Abdulrahman Theyab; Mohammad Tauhidur Rahman; Aklima Akter; Abdullah Al Mamun; Fahad A Alhumaydhi; Talha Bin Emran Journal: Evid Based Complement Alternat Med Date: 2022-06-21 Impact factor: 2.650
Authors: Daniel F Hicks; Nicolas Goossens; Ana Blas-García; Takuma Tsuchida; Benjamin Wooden; Michael C Wallace; Natalia Nieto; Abigale Lade; Benjamin Redhead; Arthur I Cederbaum; Joel T Dudley; Bryan C Fuchs; Youngmin A Lee; Yujin Hoshida; Scott L Friedman Journal: Sci Rep Date: 2017-03-03 Impact factor: 4.996